|
1
|
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.
|
Sci Transl Med
|
2012
|
3.27
|
|
2
|
Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization.
|
Am J Transplant
|
2003
|
1.64
|
|
3
|
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
|
Hepatology
|
2012
|
1.56
|
|
4
|
MRI predictors of cognitive change in a diverse and carefully characterized elderly population.
|
Neurobiol Aging
|
2010
|
1.56
|
|
5
|
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome.
|
Transplantation
|
2013
|
1.50
|
|
6
|
Heterogeneity of cognitive trajectories in diverse older persons.
|
Psychol Aging
|
2010
|
1.44
|
|
7
|
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation.
|
Transplantation
|
2002
|
1.42
|
|
8
|
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.
|
Transplantation
|
2002
|
1.32
|
|
9
|
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure.
|
Am J Transplant
|
2005
|
1.32
|
|
10
|
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.
|
Transplantation
|
2003
|
1.28
|
|
11
|
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly.
|
Arch Neurol
|
2007
|
1.26
|
|
12
|
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
|
Transplantation
|
2005
|
1.25
|
|
13
|
Allosensitization of islet allograft recipients.
|
Transplantation
|
2007
|
1.13
|
|
14
|
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.
|
Transplantation
|
2007
|
1.13
|
|
15
|
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients.
|
Transplantation
|
2002
|
1.11
|
|
16
|
Relation of plasma homocysteine to plasma amyloid beta levels.
|
Neurochem Res
|
2006
|
1.06
|
|
17
|
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation.
|
Transplantation
|
2009
|
1.06
|
|
18
|
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation.
|
Am J Transplant
|
2005
|
1.01
|
|
19
|
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
|
Transplantation
|
2007
|
1.01
|
|
20
|
Review of major clinical trials with mycophenolate mofetil in renal transplantation.
|
Transplantation
|
2005
|
1.00
|
|
21
|
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation.
|
Transplantation
|
2004
|
0.99
|
|
22
|
The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
|
Transplantation
|
2004
|
0.99
|
|
23
|
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans.
|
Transplantation
|
2013
|
0.98
|
|
24
|
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year.
|
Transplantation
|
2004
|
0.96
|
|
25
|
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants.
|
Transplantation
|
2015
|
0.96
|
|
26
|
Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation.
|
Transpl Immunol
|
2003
|
0.95
|
|
27
|
Genomic biomarkers correlate with HLA-identical renal transplant tolerance.
|
J Am Soc Nephrol
|
2013
|
0.94
|
|
28
|
A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
|
Transplantation
|
2004
|
0.94
|
|
29
|
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.
|
Transplantation
|
2011
|
0.93
|
|
30
|
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
|
Transplantation
|
2003
|
0.93
|
|
31
|
Use of older controlled non-heart-beating donors for liver transplantation.
|
Transplantation
|
2003
|
0.92
|
|
32
|
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
|
Transplantation
|
2008
|
0.92
|
|
33
|
Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation.
|
Exp Cell Res
|
2008
|
0.92
|
|
34
|
Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience.
|
Pediatr Nephrol
|
2004
|
0.92
|
|
35
|
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
|
Clin Transplant
|
2008
|
0.91
|
|
36
|
Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents.
|
Hum Immunol
|
2009
|
0.91
|
|
37
|
Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays.
|
Hum Immunol
|
2010
|
0.91
|
|
38
|
Favorable effects of alemtuzumab on allospecific regulatory T-cell generation.
|
Hum Immunol
|
2011
|
0.89
|
|
39
|
FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion.
|
Transplantation
|
2007
|
0.88
|
|
40
|
Donor bone marrow infusion in deceased and living donor renal transplantation.
|
Yonsei Med J
|
2004
|
0.88
|
|
41
|
Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
|
Transplantation
|
2002
|
0.88
|
|
42
|
Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.
|
Hum Immunol
|
2004
|
0.87
|
|
43
|
Donor bone marrow transplantation: chimerism and tolerance.
|
Transpl Immunol
|
2004
|
0.86
|
|
44
|
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis.
|
Transplantation
|
2006
|
0.86
|
|
45
|
Hypercoagulable state associated with kidney-pancreas transplantation. Thromboelastogram-directed anti-coagulation and implications for future therapy.
|
Clin Transplant
|
2004
|
0.83
|
|
46
|
Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches.
|
Hum Immunol
|
2007
|
0.83
|
|
47
|
Vascular complications of pancreas transplantation.
|
Pancreas
|
2004
|
0.82
|
|
48
|
The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
|
Am J Transplant
|
2003
|
0.81
|
|
49
|
Microchimerism in promoting graft acceptance in clinical transplantation.
|
Curr Opin Organ Transplant
|
2011
|
0.81
|
|
50
|
Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
|
Transplantation
|
2015
|
0.81
|
|
51
|
Viral interleukin-10-engineered autologous hematopoietic stem cell therapy: a novel gene therapy approach to prevent graft rejection.
|
Hum Gene Ther
|
2004
|
0.81
|
|
52
|
Plasma homocysteine and risk of mild cognitive impairment.
|
Dement Geriatr Cogn Disord
|
2008
|
0.80
|
|
53
|
A novel approach to detect donor/recipent immune responses between HLA-identical pairs.
|
Hum Immunol
|
2006
|
0.80
|
|
54
|
Role of innate and acquired immune mechanisms in clinical intestinal transplant rejection.
|
Transplantation
|
2015
|
0.79
|
|
55
|
Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells.
|
PLoS One
|
2011
|
0.79
|
|
56
|
A novel micro-cell-mediated lympholytic assay for the evaluation of regulatory cells in human alloreactive CTL responses.
|
J Immunol Methods
|
2003
|
0.79
|
|
57
|
The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants.
|
Clin Transplant
|
2003
|
0.79
|
|
58
|
Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up.
|
Transplantation
|
2008
|
0.79
|
|
59
|
Functional and phenotypic properties of peripheral T cells anergized by autologous CD3(+) depleted bone marrow cells.
|
Hum Immunol
|
2002
|
0.78
|
|
60
|
Requirement of cognate CD4+ T-cell recognition for the regulation of allospecific CTL by human CD4+ CD127- CD25+ FOXP3+ cells generated in MLR.
|
PLoS One
|
2011
|
0.78
|
|
61
|
Detection of HLA and MICA antibodies before kidney graft failure.
|
Clin Transpl
|
2006
|
0.78
|
|
62
|
Underreporting of psychopathology on the MMPI-2: a meta-analytic review.
|
Psychol Assess
|
2002
|
0.78
|
|
63
|
Host-derived enterocytes in intestinal grafts.
|
Transplantation
|
2002
|
0.78
|
|
64
|
Simultaneous pancreas-kidney transplantation in Jehovah's Witness patients.
|
Clin Transplant
|
2003
|
0.78
|
|
65
|
HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.
|
Clin Transpl
|
2013
|
0.78
|
|
66
|
Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: the Northwestern University experience.
|
Transplantation
|
2008
|
0.77
|
|
67
|
Campath-1H does not alter bone marrow cell regulatory function.
|
Hum Immunol
|
2005
|
0.77
|
|
68
|
Locomotor and resistance training restore walking in an elderly person with a chronic incomplete spinal cord injury.
|
NeuroRehabilitation
|
2010
|
0.77
|
|
69
|
Diabetic muscle infarction after simultaneous pancreas-kidney transplant.
|
Clin Transplant
|
2002
|
0.76
|
|
70
|
Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation.
|
Clin Transplant
|
2004
|
0.76
|
|
71
|
Induction of auto-reactive regulatory T cells by stimulation with immature autologous dendritic cells.
|
Immunol Invest
|
2007
|
0.76
|
|
72
|
Expression of MUC2 and MUC4 proteins and cytokines: early markers of intestinal graft rejection.
|
Transplantation
|
2003
|
0.75
|
|
73
|
Induction therapy in renal transplantation : an overview of current developments.
|
Drugs
|
2007
|
0.75
|
|
74
|
Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model.
|
Hum Immunol
|
2008
|
0.75
|
|
75
|
The influence of arterial flow on capillary refill in pediatric lower extremity.
|
J Surg Orthop Adv
|
2008
|
0.75
|
|
76
|
Best practice in unbilled account management: one medical center's story.
|
Healthc Financ Manage
|
2016
|
0.75
|
|
77
|
Ex vivo repair and renal autotransplantation after penetrating trauma: is there an upper limit of ischemic/traumatic injury beyond which a kidney is unsalvageable?
|
J Trauma
|
2003
|
0.75
|
|
78
|
Utilization of dried blood spot citrulline level as a noninvasive method for monitoring graft function following intestinal transplantation.
|
Transplantation
|
2005
|
0.75
|
|
79
|
Efficacy of alemtuzumab in organ transplantation: current clinical status.
|
BioDrugs
|
2006
|
0.75
|
|
80
|
A simple technique for aortic cannulation in organ donors with advanced aortic disease.
|
Prog Transplant
|
2002
|
0.75
|
|
81
|
Human donor bone marrow cells induce in vitro "suppressor T cells" that functionally suppress autologous B cells.
|
Hum Immunol
|
2003
|
0.75
|